Tanya Newton Named Manager, Regulatory Affairs and Compliance Operations, SAFE-BioPharma...

Tanya Newton Named Manager, Regulatory Affairs and Compliance Operations, SAFE-BioPharma Association

FT. LEE, N.J.--(Business Wire)--
Tanya Newton has been named Manager, Regulatory Affairs and
Compliance Operations for SAFE-BioPharma Association, the non-profit
association that created and manages the SAFE-BioPharma(TM) digital
identity and digital signature standard for the pharmaceutical and
healthcare industries. The SAFE-BioPharma standard was established by
the biopharmaceutical industry to help it transform to a fully
electronic environment from inefficient paper-based business and
regulatory processes.

In the newly created position, Ms. Newton supports a variety of
Association functions including Business, Governance, Compliance and
Regulatory Affairs, the SAFE-BioPharma EU Advisory Council and the
Association's working groups. She also works closely with
organizations with which SAFE-BioPharma collaborates.

Ms. Newton most recently was Manager, US Preclinical Development
Protocol & Report Operations in Johnson & Johnson's Pharmaceutical
Research and Development organization. In this role she managed
projects relating to early and late development submissions for
Preclinical Research. In addition, she was the Functional Area Lead
for US Preclinical and Global Discovery Teams for both the Documentum
and Core Dossier systems.

She holds a BA from Jones International University.

About SAFE-BioPharma Association

SAFE-BioPharma Association is the non-profit association that
created and manages the SAFE-BioPharma(TM) digital identity and
signature standard for the pharmaceutical and healthcare industries.
The SAFE-BioPharma industry standard is used to mitigate legal,
regulatory and other business risk associated with
business-to-business and business-to-regulator electronic
transactions. It facilitates interoperability by providing a secure,
enforceable, and regulatory-compliant way to verify identities of
parties involved in electronic transactions. SAFE-BioPharma's vision
is to be a catalyst in transforming the biopharmaceutical and
healthcare communities to a fully electronic business environment by
2012. The Association's members are Amgen (NASDAQ: AMGN), AstraZeneca
(NYSE: AZN), Bristol-Myers Squibb (NYSE: BMY), Genzyme (NASDAQ: GENZ),
GlaxoSmithKline (NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck
(NYSE: MRK), National Notary Association, Organon/Schering-Plough
(NYSE: SGP), Pfizer (NYSE: PFE), Procter & Gamble (NYSE: PG), Roche
and Sanofi-Aventis (NYSE: SNY). For more information, visit
www.safe-biopharma.org.

SAFE-BioPharma(TM) is a trademark of SAFE-BioPharma Association.
Any use of this trademark requires approval from SAFE-BioPharma
Association.

Photo available.

SAFE-BioPharma Association
Jon Weisberg, 801-359-9977
Mobile: 801-860-9977
Jon.weisberg@safe-biopharma.org

Copyright Business Wire 2008